Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ: FULC )

4.350 +0.320 (+7.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,277,668
Open 3.990
Bid (Size) 4.200 (5)
Ask (Size) 4.350 (1)
Prev. Close 4.030
Today's Range 3.955 - 4.390
52wk Range 2.860 - 13.70
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fulcrum Therapeutics to Participate in Upcoming December Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings For Fulcrum Therapeutics
Via Benzinga

Performance

YTD
-39.67%
-39.67%
1 Month
+46.46%
+46.46%
3 Month
+35.94%
+35.94%
6 Month
-31.39%
-31.39%
1 Year
-30.73%
-30.73%

More News

Read More
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 13, 2024
Via Benzinga
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Earnings Preview: Fulcrum Therapeutics
Via Benzinga
Fulcrum Therapeutics's Earnings Outlook
Via Benzinga
Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
Via Benzinga
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
Via Talk Markets
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Dow Surges Over 100 Points; ModivCare Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
Via Benzinga
US Stocks Mixed; Producer Prices Increase In August
Via Benzinga
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Via Benzinga
Fulcrum Therapeutics to Participate in Upcoming September Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.